Jean‐François Ramée

Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

Thierry Conroy, Florence Castan, Anthony Lopez et al. · JAMA Oncology · 2022 · 324 citations · Full text

Medicine, Oncology, Surgery +14

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Performance comparison of modified ComBat for harmonization of radiomic features for multicenter studies

Ronrick Da‐ano, Ingrid Masson, François Lucia et al. · Scientific Reports · 2020 · 193 citations · Full text

Medicine, Biostatistics, Oncology +14

Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial

Yungan Tao, J. Biau, X.S. Sun et al. · Annals of Oncology · 2022 · 177 citations · Full text

Medicine, Oncology, Radiation Oncology +13

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years

Emmanuel Gyan, Charles Foussard, Philippe B. Bertrand et al. · Blood · 2008 · 153 citations

Medicine, Hematology, Oncology +17